Unicycive Therapeutics UNCY 深 沪
等待开盘 09-18 09:30:00 美东时间
4.04
+0.050
+1.25%
华盛通- 最 高4.13
- 今 开3.98
- 成交量 37.23万股
- 最 低 3.98
- 昨 收 3.99
- 总市值 5106.92万
- 52周最高 11.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.40
- 委 比 53.35%
- 总股本 1264.09万
- 历史最高 87.30
- 量 比 0.51
- 振 幅 3.76%
- 历史最低 2.02
- 每 手 1
- 风险率 0.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股机会日报 | 市场翘首以待！美国8月零售销售数据将公布；甲骨文盘前涨超5%
今晚20:30公布！美国8月零售销售或逆势增长；知名分析师：恐慌性降息周期将开启；甲骨文盘前涨超5%，据报在中美TikTok交易中扮演关键角色>>
09-16 20:13
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $21
Benchmark analyst Bruce D. Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the price target from $3 to $21.
09-15 20:57
Unicycive Therapeutics to Participate in Upcoming Investor Events in September
Unicycive Therapeutics Inc. announced that CEO Shalabh Gupta, M.D., will participate in two investor events in September. The first is a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, and the second is a virtual fireside chat with Truist Securities on September 17, 2025. The company is developing therapies for kidney diseases, including oxylanthanum carbonate for hyperphosphatemia in chronic k...
08-26 11:00
Unicycive Faces Securities Lawsuit Over Drug Claims
Unicycive Therapeutics ( ($UNCY) ) has provided an update. On August 15, 2025, ...
08-19 04:53
Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease
Unicycive Therapeutics announced the issuance of U.S. Patent 12,377,082 for UNI-494 to treat Chronic Kidney Disease (CKD), supporting intellectual property protection until 2040. UNI-494 is a novel nicotinamide ester derivative targeting mitochondrial dysfunction in kidney diseases. The company has completed a Phase I clinical study and received Orphan Drug Designation for preventing Delayed Graft Function (DGF) in kidney transplant patients. UNI...
08-18 11:05
Unicycive Therapeutics Q2 EPS $(0.52) Beats $(0.78) Estimate
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.78) by 32.9 percent. This is a 65.33 percent increase over losses of $(1.50) per share
08-14 19:16
Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology
A Phase 2 clinical trial of Oxylanthanum Carbonate (OLC) showed that the investigational phosphate binder effectively controlled serum phosphate levels in over 90% of chronic kidney disease (CKD) patients on dialysis with hyperphosphatemia. OLC was well-tolerated, with only 4% of patients discontinuing due to adverse events, and required a low pill burden (three or fewer tablets/day for two-thirds of patients). The trial results support OLC's pot...
07-24 12:00
Unicycive Regains Nasdaq Compliance After Stock Split
Unicycive Therapeutics ( ($UNCY) ) has shared an announcement. On July 8, 2025,...
07-08 21:28
